University of Patras
Ανασυνδυασμένη πρωτεϊνική κινάση Musk και χρήση της για την ανάπτυξη αντιγονοειδικής θεραπείας της Musk - εξαρτώμενης βαριάς μυασθένειας
Abstract
dc:descriptionMyasthenia gravis (MG) is an antibody-mediated autoimmune disease that affects the neuromuscular junction (NMJ). About 85% of MG patients have antibodies against the muscle nicotinic acetylcholine receptor (AChR), while about 5-7% of patients have antibodies against the muscle specific kinase (MuSK). MuSK is important during the development of the NMJ and it is also expressed at the mature NMJ, where it mediates the agrin-induced clustering of AChRs. MuSK is a transmembrane protein which consists of an extracellular region, a transmembrane domain and an intracellular, tyrosine kinase, catalytic domain. The extracellular domain (ECD) consists of three immunoglobulin–like (Ig) domains and a cysteine-rich domain (CRD). Current treatments of MG, such as cholinesterase inhibitors, immunosuppressive agents, intravenous immunoglobulin, thymectomy and plasmapheresis, are non specific, causing several side effects such as the removal of indispensable plasma components observed by plasmapheresis. We aim to develop an antigen-specific therapy in which only MuSK antibodies will be removed from patients’ sera using the immobilized MuSK-ECD as immunoadsorbent. Furthermore, the above treatments are not specific for the removal of the pathogenic antibodies and also, they have high cost and limited availability for the patients. The selective removal of MuSK antibodies from the blood of MuSK-MG patients with an extracorporeal technique similar to plasmapheresis could be a therapeutic option. The method is based on the immobilization of the extracellular domain (ECD) of MuSK as immunoabsorbent in an appropriate substrate for the construction of immunoadsorption columns which remove the MuSK antibodies from the MuSK-MG sera.The purpose of the current project was the expression of the ECD of MuSK in different expression systems in high amounts with appropriate conformation for the recognition of the majority of the MuSK antibodies and their use as immunoabsorbents. For the development of the appropriate immunoabsorbents, two different proteins were expressed; the one consisted of the whole ECD of MuSK (MuSK-ECDf) and the other was smaller because of the lack of the cysteine-rich region (MuSK-ECDΔFz). All efforts for protein expression in COS-7, HEK293 and E. coli were not successful because either the expression proteins were not in appropriate conformation or they worked not efficiently as immunoabsorbents. However, both proteins were expressed successfully in the heterologous system P. pastoris as secreted soluble proteins with satisfactory expression yields and much higher expression yield of MuSK-ECDΔFz than that of MuSK-ECDf. After the protein purification using metal affinity and gel filtration chromatography, the proteins were immobilized on CNBr activated sepharose beads and characterized as immunoabsorbents. Both immunoabsorbents remove effectively the majority of the MuSK antibodies from MG patients’ sera with the MuSK-ECDΔFz immunoadsorbent to show lower binding affinity in some sera. Further, both immunoaborbents are specific for the MuSK antibodies, show high binding capacity, are recyclable, can be stored effectively and are stable during the immunoadsorption. Furthermore, animal experiments showed that the ex-vivo clearance of plasma with the immobilized MuSK-ECDf had no toxic effects in rabbits. Finally, passive transfer experiments in mice showed the effectiveness of the immunoadsorption columns regarding the removal of the MuSK antibodies from patients’ sera and also, the pathogenicity of the removed MuSK antibodies.In conclusion, the above results are expected to lead to a therapeutic approach using the MuSK-ECD as specific immunoadsorbent for the ex vivo clearance of the MuSK-MG plasma and in parallel with a small cost for the patient.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Skriapa, Lamprini
- Σκριάπα, Λαμπρινή
Subjects
dc:subject × 7Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/35593